MDMA Plus Exposure Therapy for PTSD
Key facts
- Who runs it
- Emory University
- Where
- Atlanta, United StatesSee the site
- Trial code
- Status
- Enrolling by invitation
- Phase
- Phase 2
- People taking part
- 40 people, planned
- Started
- 13 Feb 2024
- Planned end
- 31 Oct 2026
- Type of study
- Interventional
- Treatments tested
- MDMA
- Record updated
- 8 July 2026
Who can take part
- Age
- 21 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Meet criteria for PTSD
- Willingness of the participant to sign a release for the investigators to communicate with their primary care or mental health providers if indicated
- Are able to visually read and understand the English language and give written informed consent
- Are able to swallow pills
- Agree to have study visits and treatment sessions video and/or audio recorded,
- Must provide a contact (relative, spouse, close friend, or another support person) who is willing and able to be reached by the investigators
- Must agree to inform the investigators within 48 hours of any medical conditions and procedures
- If able to become pregnant, must have a negative pregnancy test prior to study entry, at study entry, and prior to the Medicine Session. Must agree to use adequate birth control for a month prior to the Medicine session and through 10 days after the Medicine session
- Agree to the following lifestyle modifications: comply with requirements for fasting and refraining from certain medications prior to Medicine Session, and not participate in any other interventional clinical trials during the duration of the study and are driven home or to a hotel after the Medicine Session, and commit to medication dosing, therapy, and study procedures
Who cannot take part
- Have previously participated in a Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored MDMA clinical trial
- Have a history of any medical condition that could make receiving MDMA dangerous because of increases in blood pressure and heart rate or any medical condition the study physician believes would pose a safety risk or interfere with the effects of the treatment. Any medical disorder judged by the investigator to significantly increase the risk of MDMA administration by any mechanism is exclusionary
- Require the use of concomitant medications that could impact the effects or safety of MDMA during the Medicine Session
- Have engaged in ketamine-assisted therapy or used ketamine within 12 weeks of enrollment
- Have hypersensitivity to any ingredient of the Investigational Medicinal Product (IMP)
- Upon review of medical or psychiatric history and assessment, have any current or past diagnosis that would be considered a risk to participating in the study
- Requires ongoing psychiatric medication use with certain exceptions. Individuals may decide to taper psychiatric medications under the guidance of their local provider
- Have any unstable medical condition that would interfere with participation
- Have uncontrolled hypertension) documented on three separate occasions
- Have Wolff-Parkinson-White syndrome or any other accessory pathway that has not been successfully eliminated by ablation
- Have a history of ever having ventricular arrhythmia or any other abnormal heart rhythm that the study physician believes would pose a significant risk of participation
- Have symptomatic liver disease or significant liver enzyme elevations
- Have a history of hyponatremia or hyperthermia
- Have a history of additional risk factors for Torsade de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
- Are not able to give adequate informed consent
- Have any current problem which, in the opinion of the investigator or study physician might interfere with participation
- Current or past substance abuse that would be considered a risk for participating in the study
- Have an abnormal finding on electrocardiogram
- Weigh less than 48 kilograms (105 lbs.)
- Are pregnant or nursing
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 21 and 70 years old?
Where in United States
- Emory Brain Health CenterAtlanta, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
Posttraumatic stress disorder (PTSD) is a debilitating disorder. While effective treatments exist, some patients fail to receive the full benefits. Alternative treatment approaches are needed. 3,4-methylenedioxymethamphetamine (MDMA) is a medicine associated with feelings of closeness and love for others, empathy, insightfulness, and feelings of peace or well-being. Recent research combining one or two doses of MDMA with psychotherapy has shown improvements in PTSD symptoms.
Read full original descriptionShow less
For the present study, the researchers will investigate MDMA in combination with Prolonged Exposure therapy (PE), a gold-standard treatment for PTSD. All participants receive MDMA on the second day of a 10-day PE treatment program in which a PE therapy session occurs each day. This study will occur at the Emory Brain Health Center. Potential participants will be recruited via community advertising and mental health referrals.
The research team will also collect psychophysiological data for exploratory analyses regarding how MDMA may improve PE treatment for PTSD. This is an important study as it is the first time MDMA will be combined with an evidence-based existing PTSD treatment.
The study population will consist of people who meet the criteria for PTSD and are medically appropriate for MDMA administration.
The group in the trial
- Medicine SessionTreatment being tested
3,4-methylenedioxymethamphetamine (MDMA) in combination with massed exposure therapy for PTSD
Treatment: MDMA
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Pilot Study of MDMA-Assisted Massed Exposure Therapy for PTSD (MDMA PE)
- Criteria questions
- Built from NCT05746572, who can take part
- Publications
- The METEMP protocol: Massed exposure therapy enhanced with MDMA for PTSD.Contemporary clinical trials communications, 2025
- Record updated
- 8 July 2026